Skip to main content

Advertisement

SpringerLink
Log in

Fumaric acid esters for psoriasis: a systematic review

  • Review Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

Psoriasis is a chronic skin disease associated with increased morbidity and mortality. Effective and safe long term treatment options are required to manage the illness successfully. A number of systemic agents are available, however, each of them has potentially significant side effects. Fumaric acid esters (FAE) are used first line in Germany for the management of moderate to severe psoriasis, however, their use in Ireland is on an unlicensed basis (Clinical and Experimental Dermatology 37:786–801, 2012).

Objectives

The purpose of this literature review is to evaluate the efficacy and safety of FAEs in the management of moderate to severe psoriasis in adult patients. The reviewer intends to systematically review all available literature on the efficacy and/or safety of fumaric acid esters in the management of moderate to severe psoriasis in adult patients.

Methods

A systematic review of the literature was performed by one reviewer. The PubMed, TRIP, Embase, and Cochrane Collaboration databases were systematically interrogated to include randomised controlled trials, cohort studies and case studies evaluating the efficacy and/or safety of FAEs in the management of moderate to severe psoriasis in adult patients. Inclusion criteria were studies which included adults over 18 years of age, with a diagnosis of moderate to severe chronic plaque psoriasis, who were treated with FAEs and no other systemic anti-psoriatic agents concurrently. Exclusion criteria were studies involving children, mild psoriasis, studies which did not include patients with chronic plaque psoriasis, the use of FAE for the management of illnesses other than psoriasis, and patients treated with more than one systemic anti-psoriatic agent concurrently.

Results

In total 19 articles were selected for review including 2 randomised placebo controlled trials, 1 non-randomised comparative study, 7 retrospective cohort studies, 2 prospective cohort studies and 7 case studies. The findings suggest that FAEs are a safe and effective treatment option for the management of moderate to severe psoriasis in adult patients. Gastrointestinal side effects may occur on treatment initiation and may be minimised by slow dose titration. Lymphocytopenia and eosinophilia are common, however, they are rarely of significance and there is no high level of evidence available to suggest a resultant increased risk of infection or malignancy. Rarely alterations of renal and hepatic function may occur, however, these are largely reversible on treatment withdrawal.

Conclusion

In conclusion, the use of FAE in the management of moderate to severe psoriasis is a promising treatment option, especially for those patients intolerant of, or unresponsive to other agents. If blood parameters are closely monitored during treatment as per the European Medicine Agencies guidelines (European Medicines Agency, ‘Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera’, http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/10/WC500196017.pdf, 2015) they may be safely used in practice. The licensing of FAEs in Ireland for the treatment of moderate to severe psoriasis would be desirable, increasing available treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Altmeyer PJ, Matthes U, Pawlak F et al (1994) Antipsoriatic effect of fumaric acid derivatives: results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30:977–981

    Article  CAS  PubMed  Google Scholar 

  2. Barth D, Simon JC, Wetzig T (2011) ‘Malignant melanoma during treatment with fumaric acid esters—coincidence or treatment related? JDDG. J der Deutschen Dermatologischen Gesellschaft 3:223–224

    Google Scholar 

  3. Brewer L, Rogers S (2007) Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol 32:246–249

    Article  CAS  PubMed  Google Scholar 

  4. Carboni I, De Felice C, De Simoni I et al (2004) Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatol Treat 15:23–26

    Article  CAS  Google Scholar 

  5. Ermis U, Weis J, Schulz JB (2013) PML in a patient treated with fumaric acid. N Engl J Med 368(17):1657–1658

    Article  CAS  PubMed  Google Scholar 

  6. Fairhurst DA, Ashcroft DM, Griffiths EM (2005) ‘Optimal Management of Severe Plaque Form of Psoriasis. Am J Clin Dermatol 6(5):283–294

    Article  PubMed  Google Scholar 

  7. Fika Z, Williams REA, Williamson DJ (2006) Fumaric acid esters in psoriasis. Br J Dermatol 154(3):567–568

    Article  CAS  PubMed  Google Scholar 

  8. Harries MJ, Chalmers RJG, Griffiths CEM (2005) Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol 153:549–551

    Article  CAS  PubMed  Google Scholar 

  9. Heelan K, Markham T (2012) Fumaric acid esters as a suitable first line treatment for severe psoriasis: an Irish experience. Clin Exp Dermatol 37:786–801

    Article  Google Scholar 

  10. Hoefnagel JJ, Thio HB, Willemze R et al (2003) Long term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 149:363–369

    Article  CAS  PubMed  Google Scholar 

  11. Ismail N, Collins P, Rogers S et al (2014) Drug survival of fumaric acid esters for psoriasis: a retrospective study. Br J Dermatol 171:397–402

    Article  CAS  PubMed  Google Scholar 

  12. Jennings L, Murphy GM (2009) Squamous cell carcinoma as a complication of fumaric acid ester immunosuppression. Eur Acad Dermatol Venereol 23:1445–1469

    Article  Google Scholar 

  13. Kolbach DN, Niebor C (1992) ‘Fumaric acid therapy in psoriasis: Results and side effects of 2 years of treatment’. J Am Acad Dermatol 27(5 part 1): 769–771

  14. Mrowietz U, Christophers E, Altmeyer P (1998) Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. Br J Dermatol 141:424–429

    Article  Google Scholar 

  15. Naldi L, Griffiths CEM (2005) Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 152:597–615

    Article  CAS  PubMed  Google Scholar 

  16. Nugteren-Huying WM, van der Schroeff JG, Hermans J et al (1990) Fumaric acid therapy for psoriasis: a randomised, double blind, placebo controlled study. J Am Acad Dermatol 22(2):311–312

    Article  CAS  PubMed  Google Scholar 

  17. Ogilvie S, Lewis Jones S, Dawe R et al (2011) Proteinuria with fumaric acid ester treatment for psoriasis. Clin Exp Dermatol 36:632–634

    Article  CAS  PubMed  Google Scholar 

  18. Pathirana D, Ormerod AD, Saiag P et al (2009) ‘European S3- Guidelines on the systemic treatment of psoriasis vulgaris. Eur Acad Dermatol Venereol 23(2):5–70

    Google Scholar 

  19. Raschka C, Koch HJ (1999) Long term treatment of psoriasis using fumaric acid preparations can be associated with severe proximal tubular damage. Hum Exp Toxicol 18:738–739

    Article  CAS  PubMed  Google Scholar 

  20. Reich K, Thaci D, Mrowietz U et al (2009) Efficacy and safety of fumaric acid esters in the long term treatment of psoriasis- a retrospective study (FUTURE). JDDG. J der Deutschen Dermatologischen Gesellschaft 7:603–610

    Google Scholar 

  21. Reid C, Holian J, Kane D et al (2013) De Toni Fanconi Syndrome secondary to fumaric acid esters. Br J Dermatol 169(1):24

    Article  Google Scholar 

  22. Schmitt J, Zhang Z, Wozel G et al (2008) Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate to severe psoriasis: meta-analysis of randomised controlled trials. Br J Dermatol 159:513–526

    Article  CAS  PubMed  Google Scholar 

  23. Sladden MJ, Osborne JE, Hutchinson PE (2006) Fumaric acid esters for severe psoriasis: the Leicestershire experience. Br J Dermatol 155:841–865

    Article  Google Scholar 

  24. Thaçi D, Weisenseel P, Philipp S et al (2013) ‘Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions – a retrospective evaluation (FACTS). J Ger Soc Dermatol 1610–0379:439–445

    Google Scholar 

  25. Van Oosten BW, Killestein J, Barkhof F et al (2013) PML in a patient treated with dimethylfumarate from a compounding pharmacy. N Engl J Med 368(17):1658–1659

    Article  PubMed  Google Scholar 

  26. Wu Y, Mills D, Bala M (2008) Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 7:373–377

    PubMed  Google Scholar 

  27. European Medicines Agency (2015). ‘Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera’. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/10/WC500196017.pdf. Accessed Mar 1, 2016

Download references

Acknowledgments

With special thanks to Dr Bart Ramsay, Consultant Dermatologist, University Hospital Limerick.

Author information

Authors and Affiliations

  1. Department of Dermatology, University Hospital Limerick, Limerick, Ireland

    D. Smith

Authors
  1. D. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Smith.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Smith, D. Fumaric acid esters for psoriasis: a systematic review. Ir J Med Sci 186, 161–177 (2017). https://doi.org/10.1007/s11845-016-1470-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-016-1470-2

Keywords

Search

Navigation